Discussion
In a real-world study of adults living with neuromyelitis optica spectrum disorder (NMOSD) in Japan, Uplizna (inebilizumab) was linked to fewer relapses, generally stable disability, and less use of corticosteroids. In addition, the approved therapy’s safety profile was consistent with what had been observed in earlier studies. “Our…